Singapore-based facility management company AcroMeta Group Limited has announced a strategic move into the healthcare logistics sector through a proposed partnership with Macro HRD SG Pte. Ltd., a Singapore-based management consultancy for the healthcare industry. The non-binding term sheet outlines AcroMeta's intention to acquire a strategic stake in Macro-ATCLS Pte. Ltd., the entity commercialising Macro's Ambient Temperature Cellular Logistics (ATCLS) technology, and includes an option for an exclusive licence to deploy the technology across Southeast Asia.
The ATCLS technology aims to eliminate the need for conventional refrigerated or cryogenic cold chains when transporting living cells and other temperature-sensitive biological materials. Using proprietary ambient-temperature preservation and reactivation methods, along with the Gradient Equilibrium Decision Modeling (GEDM) platform for real-time governance and process control, the technology enables dormant living cells to be transported at ambient temperatures and reactivated at their destination. This approach could significantly reduce the cost, fragility, and geographic limitations associated with traditional cold-chain logistics.
The potential market for this technology is substantial. According to data provided by Macro's management, the global cell-and-gene-therapy 3PL market is projected to grow from US$1.81 billion in 2025 to US$16.95 billion by 2035, representing a compound annual growth rate of 25.1%. The underlying markets cited include immune-cell therapy (US$5.2 billion), organ transplantation (US$47 billion), and others such as stem cells and regenerative medicine. ATCLS estimates a serviceable addressable market of approximately US$14.5 billion by 2032 for defined ambient-addressable segments.
Lawrence Toh, Executive Director of AcroMeta, commented, "This proposed strategic partnership gives us the opportunity to build a position in an industry where cell and gene therapy logistics are expected to grow at double-digit rates in the years ahead. We see this as a natural extension of our strategy to grow our portfolio beyond our core operations, and we're excited about the potential to build a meaningful presence in bringing this technology into Southeast Asia."
Under the proposed exclusive licensing arrangement, AcroMeta would secure the rights to develop and commercialise ATCLS within agreed territories in Southeast Asia, including the ability to appoint sub-licensees. This structure also provides AcroMeta with a first right to acquire additional territories, potentially expanding its commercial reach further.
The strategic partnership aligns with AcroMeta's broader growth strategy, as the company intends to continue evaluating opportunities that support long-term value creation for shareholders. The board remains focused on disciplined capital allocation during this next phase of development.
For more information on AcroMeta, visit www.AcroMeta.com. The original press release is available on NewMediaWire.
